FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
The OncoAlert Newsletter is now out for June 23-29, 2023
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant…
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed…
Abstract. PURPOSE: Early intervention for High-Risk Smoldering Multiple Myeloma (HR-SMM) achieves deep and prolonged responses. It is unclear if beneficial outcomes are due to treatment…
1 ADDIPSY, Outpatient Addictology and Psychiatry Center, Sant é Basque D é veloppement Group, Lyon, France 2 Universit é Paris-Saclay, Universit é de Versailles Saint-Quentin-en-Yvelines…
Androgen receptor signaling is crucial for the development of treatment resistance in prostate cancer. Among steroidogenic enzymes, 3β-hydroxysteroid dehydrogenases (3βHSDs) play critical roles in extragonadal…
ctDNA assays are quickly finding their way into the clinic. These assays have a potential role to play in all phases of the cancer continuum…
Semaglutide and liraglutide are sold under the brand names Wegovy, Ozempic, Rybelsus and Saxenda and are manufactured by Novo Nordisk